Ovarian Cancer: Clinical Trials

2,102 trials for Ovarian Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

937 completed, 334 recruiting, 297 unknown, 250 terminated. 763 Phase 2, 628 Phase 1, 290 Not applicable, 168 Phase 3, 28 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2763Completed 350, Terminated 126, Recruiting 101, Unknown 88, Active not recruiting 40, Withdrawn 33, Not yet recruiting 24, Enrolling by invitation 1
Phase 1628Completed 282, Recruiting 111, Terminated 111, Unknown 44, Active not recruiting 39, Withdrawn 25, Not yet recruiting 11, Suspended 4, Enrolling by invitation 1
Not applicable290Completed 124, Recruiting 59, Unknown 41, Active not recruiting 20, Not yet recruiting 17, Terminated 17, Withdrawn 8, Enrolling by invitation 4
Phase 3168Completed 73, Recruiting 30, Unknown 25, Terminated 17, Active not recruiting 13, Not yet recruiting 5, Withdrawn 4, Suspended 1
Early Phase 128Completed 12, Not yet recruiting 6, Unknown 6, Terminated 3, Suspended 1
Phase 420Completed 11, Unknown 3, Not yet recruiting 2, Recruiting 2, Terminated 2

Follow Ovarian Cancer: new trials by email Literature Review of Ovarian Cancer trials Research Report on Ovarian Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors
Exercise and dietary recommendations - Ovarian Cancer
Not applicableNot yet recruitingOncare Madrid322028-05-012026-10-08
Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
Indocyanine Green, Near-Infrared Fluorescence Imaging System - Gynecologic Cancers, Ovarian Cancer
Phase 4Not yet recruitingIstanbul University502027-06-012026-11-18
PITCH - Impacting Hereditary Cancer Testing
Genetic testing education video - Ovarian Cancer, Genetic Testing
Not applicableNot yet recruitingRachel Miller2002027-04-012026-09-10
NK521 in the Treatment of Advanced Solid Tumors
NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer
Early Phase 1Not yet recruitingBase Therapeutics (Shanghai) Co., Ltd.182027-01-012026-09-30
Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab
Fludarabine, Cyclophosphamide - Ovarian Cancer
Phase 2Not yet recruitingMedical University of South Carolina202026-12-012026-07-22
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
LG00313112 - Ovarian Cancer, Small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingLG Chem2502026-12-012026-08-07
Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1
INCB123667, Bevacizumab, Placebo - Ovarian Cancer
Phase 3Not yet recruitingIncyte Corporation5902026-12-012026-10-02
Identifying Mediators of Exercise-induced Tumor Microenvironment Remodeling to Enhance Primary Chemotherapy Response (IMPROVE-Ovarian)
Exercise, Usual Care - High Grade Serous Ovarian, Ovarian Adenocarcinoma
Not applicableNot yet recruitingUniversity of Pittsburgh202026-12-012026-11-12
CYTALUX Dose Extension Study
CYTALUX (pafolacianine) injection - Cancer in the Lung, Ovarian Cancer
Phase 4Not yet recruitingOn Target Laboratories, LLC1062026-11-152026-11-09
Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors
QLS5133; Lenvatinib mesylate, QLS5133; QL2107; Lenvatinib mesylate, QLS5133; Bevacizumab - Clear Cell Renal Cell Carcinoma, Ovarian Cancer
Phase 1 / Phase 2Not yet recruitingQilu Pharmaceutical Co., Ltd.5582026-11-152026-11-12
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
CryptiVax-1001 - Ovarian Cancer, HGSOC
Phase 1RecruitingEpitopea Ltd502026-11-052026-11-10
Safety in Ovarian Cancer for Average-Risk Women - Analysis
Blood-Based Ovarian Cancer Screening Test - Ovarian Cancer
Not applicableNot yet recruitingMercy BioAnalytics, Inc.17502026-11-012026-10-16
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer
Rina-S, Bevacizumab - Ovarian Cancer
Phase 3Not yet recruitingGenmab6022026-11-012026-10-05
AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery
Ovarian Cancer, Ovarian Tumor
Not yet recruitingCatharina Ziekenhuis Eindhoven13002026-11-012026-10-20
Effects of Web-Based Ovarian Cancer Awareness Education on Women's Health Beliefs and Risk-Reducing Behaviors
Web-Based Ovarian Cancer Awareness Education, General Reproductive Health Information - Ovarian Cancer
Not applicableNot yet recruitingEge University822026-11-012026-10-22
Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry
Proton Transfer Reaction Mass Spectrometry Analysis - Pancreas Cancer, Hepatocellular Carcinoma
Not yet recruitingUniversity of Oklahoma20002026-11-012026-11-18
Peer Ambassador in Gyn Onc Trials
Mentee encounters - Ovarian Cancer
Not applicableEnrolling by invitationAbramson Cancer Center at Penn Medicine1252026-10-302026-11-09
Phase 1 Study of VT-101 in Advanced Ovarian Cancer
VT-101 - Epithelial Ovarian Cancer, Ovarian Cancer
Phase 1RecruitingMichael J. Goodheart222026-10-262026-11-09
Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingPeking University Cancer Hospital & Institute532026-10-222026-10-01
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
CR-002 - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ
Phase 1 / Phase 2RecruitingCrescent Biopharma, Inc.2192026-10-212026-11-02

Showing 20 of 2102. Sign in to see all of them.

Narrower conditions

Ovarian Neoplasms (2102)  ·  Fallopian Tube Neoplasms (389)  ·  Breast Neoplasms (383)  ·  Carcinoma, Ovarian Epithelial (352)  ·  Endometrial Neoplasms (252)  ·  Uterine Cervical Neoplasms (199)  ·  Colorectal Neoplasms (182)  ·  Carcinoma, Non-Small-Cell Lung (181)  ·  Pancreatic Neoplasms (173)  ·  Neoplasms (162)  ·  Lung Neoplasms (158)  ·  Prostatic Neoplasms (142)  ·  Stomach Neoplasms (140)  ·  Sarcoma (120)  ·  Melanoma (107)

Broader conditions

Endocrine Gland Neoplasms (2102)  ·  Female Urogenital Diseases (2102)  ·  Female Urogenital Diseases and Pregnancy Complications (2102)  ·  Genital Diseases (2102)  ·  Gonadal Disorders (2102)  ·  Urogenital Diseases (2102)  ·  Adnexal Diseases (2101)  ·  Endocrine System Diseases (2101)  ·  Neoplasms by Site (2098)  ·  Genital Diseases, Female (2097)  ·  Urogenital Neoplasms (2093)  ·  Genital Neoplasms, Female (2091)  ·  Ovarian Diseases (2089)  ·  Neoplasms (1940)  ·  Neoplasms by Histologic Type (721)

Interventions

Carboplatin (219)  ·  Paclitaxel (219)  ·  Bevacizumab (111)  ·  Topotecan (68)  ·  Gemcitabine (66)  ·  Cyclophosphamide (62)  ·  Cisplatin (61)  ·  liposomal doxorubicin (59)  ·  pembrolizumab (58)  ·  olaparib (52)  ·  niraparib (43)  ·  Docetaxel (39)  ·  Filgrastim (38)  ·  Etoposide (30)  ·  Drug Therapy (28)

Sponsors

Memorial Sloan Kettering Cancer Center (75)  ·  National Cancer Institute (NCI) (47)  ·  Gynecologic Oncology Group (43)  ·  M.D. Anderson Cancer Center (42)  ·  AstraZeneca (32)  ·  Dana-Farber Cancer Institute (31)  ·  Fondazione Policlinico Universitario Agostino Gemelli IRCCS (27)  ·  Masonic Cancer Center, University of Minnesota (24)  ·  Eli Lilly and Company (18)  ·  ARCAGY/ GINECO GROUP (16)  ·  Hoffmann-La Roche (15)  ·  University Health Network, Toronto (15)  ·  AGO Study Group (14)  ·  Abramson Cancer Center at Penn Medicine (14)  ·  European Organisation for Research and Treatment of Cancer - EORTC (14)

Countries

United States (1080)  ·  China (240)  ·  United Kingdom (189)  ·  France (165)  ·  Italy (162)  ·  Canada (159)  ·  Spain (141)  ·  Belgium (109)  ·  Germany (106)  ·  Australia (105)  ·  South Korea (88)  ·  Netherlands (76)  ·  Denmark (71)  ·  Israel (54)  ·  Japan (54)

Top investigators

Paul Sabbatini, MD (12)  ·  Franco Muggia, MD (7)  ·  Francesco Perrone, M.D., Ph.D. (6)  ·  Jalid Sehouli (6)  ·  Peter G. Rose, MD (6)  ·  Sandro Pignata, M.D., Ph.D. (6)  ·  Amit Oza, M.D. (5)

Results publications

PMID 37185961, PMID 37407274, PMID 35170751, PMID 30633128, PMID 16394300, PMID 20818904, PMID 29342393, PMID 35397664, PMID 35537408, PMID 12826431, PMID 16882940, PMID 16966687, PMID 17949799, PMID 19238149, PMID 19282241, PMID 19427025, PMID 21941283, PMID 24637997, PMID 26707054, PMID 28935273, PMID 31685558, PMID 36459691, PMID 36718018, PMID 39123210, PMID 39695768, PMID 40443562, PMID 10481771, PMID 11165129, PMID 11181662, PMID 11410496, PMID 11704843, PMID 11705489, PMID 11870167, PMID 11919245, PMID 12065559, PMID 12082455, PMID 12082456, PMID 12114401, PMID 12528778, PMID 12586591, PMID 12694666, PMID 12713990, PMID 12829663, PMID 12893206, PMID 12957454, PMID 14534883, PMID 14615449, PMID 14645425, PMID 14656276, PMID 14701774

NIH funding

2018 (13), 2023 (12), 2008 (11), 2017 (9), 2009 (8), 2016 (8), 2025 (8), P30CA008748 (7), P30CA033572 (7), U10CA032102 (7), 2015 (6), P30CA043703 (6), P30CA015083 (5), P30CA068485 (5), 2019 (4)